Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 628 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Non-communicable Disease Clear all

Conditions: Chronic Hepatitis C
Interventions: standard of care, fluvastatin; Drug
Lead sponsor: Bader, Ted, M.D.; Individual
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Microcystic Lymphatic Malformation
Interventions: QTORIN 3.9% Rapamycin Anhydrous Gel; Drug
Lead sponsor: Palvella Therapeutics, Inc.; Industry
Eligibility: 3 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 15
States / cities: Irvine, California • Palo Alto, California • Atlanta, Georgia + 12 more

Conditions: Adenovirus
Interventions: Brincidofovir; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 2 Months to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 22
States / cities: Los Angeles, California • Washinton, District of Columbia • Atlanta, Georgia + 17 more

Conditions: HIV Seroconversion, Stimulant Abuse
Interventions: Truvada; Drug
Lead sponsor: Friends Research Institute, Inc.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis
Interventions: Intravitreal injection 440mcg, Intravitreal injection of sirolimus 880mcg; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Chronic Hepatitis B Infection
Interventions: Pevifoscorvir Sodium (ALG-000184); Drug
Lead sponsor: Aligos Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Orlando, Florida • Tampa, Florida

Conditions: Intermediate Uveitis, Posterior Uveitis
Interventions: dexamethasone, Sham injection; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: amphotericin B deoxycholate, nystatin; Drug
Lead sponsor: Aronex Pharmaceuticals; Industry
Eligibility: 2 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2007
U.S. locations: 59
States / cities: Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 47 more

Conditions: COVID-19
Interventions: REGN10933+REGN10987 combination therapy, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 57
States / cities: Mesa, Arizona • Tucson, Arizona • Canoga Park, California + 48 more

Conditions: Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions: 40 mg MSB11022; Drug
Lead sponsor: Fresenius Kabi SwissBioSim GmbH; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Communicable Diseases, Opportunistic Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Covid19, Coronavirus Infection, Pneumonia
Interventions: Antibiotic; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: MAC Lung Disease, Treatment Refractory MAC Lung Disease
Interventions: Epetraborole, Placebo; Drug
Lead sponsor: AN2 Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 49
States / cities: Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 39 more

Conditions: Cancer
Interventions: fluconazole, itraconazole; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 13 Years and older
Enrollment: 578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Vaccine Exposure During Pregnancy
Interventions: Data collection; Other
Lead sponsor: VBI Vaccines Inc.; Industry
Eligibility: Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: HIV Infections, Hypercholesterolemia, Hypertriglyceridemia, Diabetes Mellitus
Interventions: Niacin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 16
States / cities: Los Angeles, California • San Diego, California • Stanford, California + 8 more

Conditions: Mycoplasma Genitalium, Non-gonococcal Urethritis (NGU)
Interventions: Tinidazole; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Interventions: ISL, ULO, BIC/FTC/TAF, Placebo for BIC/FTC/TAF, Placebo to ISL/ULO, ISL/ULO; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 570 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 24
States / cities: Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 20 more

Conditions: Non Infectious Uveitis
Interventions: DE-109 Intravitreal Injections, Sham Procedure, DE-109 Intravitreal Injections (Open Label); Drug · Other
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 38
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more

Conditions: Lymphoma, AIDS-related, Lymphoma, Large B-Cell, Diffuse
Interventions: Rituximab, Filgrastim, EPOCH; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer, Lymphoma
Interventions: DNA analysis, RNA analysis, gene expression analysis, polymorphism analysis, biologic sample preservation procedure, flow cytometry, medical chart review; Genetic · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 14
States / cities: La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 9 more

Conditions: HIV Infections, Lipodystrophy
Interventions: raltegravir; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • Cleveland, Ohio + 1 more

Conditions: Hepatitis C
Interventions: Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a; Drug · Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 27
States / cities: Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 24 more

Search by objective public record fields.

Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin

SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304

Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men

Intravitreal Sirolimus as Therapeutic Approach to Uveitis

Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis

Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer

COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy

Utility of Empiric Antibiotics for Non-intubated Novel Coronavirus Diseases 2019 Patients

Reasons for Non-treatment of Hepatitis C in HCV Mono-infected Patients Versus HCV-HIV Co-infected Patients in a University Setting

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation

PREHEVBRIO Pregnancy Outcomes Registry

Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients

"Sexual Health Assessment of TinidaZole Against M. Genitalium (SHAZAM)"

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies

Raltegravir Therapy for Women With HIV and Fat Accumulation

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C